AITG Air Transport Group Holdings

Pharmagreen Begins Site Work for the Cannabis Biotech Tissue Culture Complex

Pharmagreen Begins Site Work for the Cannabis Biotech Tissue Culture Complex

CARSON CITY, NV, Nov. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Pharmagreen Biotech, Inc. (OTC PINKS: PHBI), is pleased to announce that its Canadian subsidiary, WFS Pharmagreen Inc., has started  pre-construction ground work. The site work has started for the drilling of three water wells that will supply the Cannabis Biotech Complex commenced on October 31, 2018.  Two wells will be used for primary water supply and the third well will be for back up...  The water discharge from the irrigation system will be recycled, filtered and reused to minimize the facility’s demand on the natural water supply. The entire facility is being engineered with 100% redundancy to ensure there is no disruption to the operations 365 days a year.  This state of the art facility is designed to include not only with the latest technologies but also with green technologies.

Commenting on Pharmagreen Biotech’s progress, Peter Wojcik, President and CEO, stated, “This is very exciting moment as we have started the initial site preparation work.”

About Pharmagreen Biotech, Inc. and WFS Pharmagreen Inc.

WFS Pharmagreen Inc. is a wholly owned Canadian based subsidiary of Pharmagreen Biotech, Inc., a publicly traded (OTC PINKS: PHBI) company. WFS Pharmagreen Inc. is a cannabis company that is becoming the largest producer of cannabis plantlets through a proprietary tissue culture process with opportunity to become one of the largest players globally. Pharmagreen’s mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same plantlets of cannabis and other flora while offering full spectrum DNA testing for plant identification, live genetics preservation using  low temperature storage for various cannabis and horticulture plants; extraction of botanical oils mainly CBD oil, and to deliver laboratory based services to the North American Cannabis and agriculture sectors.  For further information on the company progress on the construction of a 63,000 square foot “Cannabis Biotech Complex” please visit 

Safe Harbor Statement

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include: our inability to obtain additional financing on acceptable terms; risk that our products and services will not gain widespread market acceptance; inability to compete with others who provide comparable products; the failure of our technology; the infringement of our technology with proprietary rights of third parties; inability to respond to consumer demands; inability to replace significant customers; seasonal nature of our business. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words "believe," "expect," "anticipate," "estimate," "project," "plan," "should," "intend," "may," "will," "would," "potential," and similar expressions may be used to identify forward-looking statements. 

The OTC Markets or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release that has been prepared by management. 

Contact Information:

Tel: (702) 803 9404
Email:  
EN
05/11/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Air Transport Group Holdings

 PRESS RELEASE

Pharmagreen Biotech Inc. (PHBI) Announces Exciting Revenue Potential f...

Pharmagreen Biotech Inc. (PHBI) Announces Exciting Revenue Potential for Its Project CARSON CITY, Nev., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Pharmagreen Biotech, Inc. (OTC PINKS: PHBI) ("Pharmagreen" or the "Company") is thrilled to highlight the significant revenue potential from its latest project under development. During a special session on Creative Spaces, hosted on X on Monday, October 7, 2024, CEO Peter Wojcik shared exciting insights into the company's business advancements and growth strategies. Pharmagreen is developing a specialized form of cannabis oil known as Live Rosin, a...

 PRESS RELEASE

Pharmagreen Biotech, Inc. (PHBI) Reaffirms Commitment to Non-Toxic Fin...

Pharmagreen Biotech, Inc. (PHBI) Reaffirms Commitment to Non-Toxic Financing Amid Ongoing Business Development Progress CARSON CITY, NV, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Pharmagreen Biotech, Inc. (OTC PINKS: PHBI) ("Pharmagreen" or the "Company") is pleased to announce the continued advancement of its business development efforts on a significant project in collaboration with a foreign government. Considerable progress has been made, and the Company is optimistic about the wide-ranging benefits this initiative will bring to all involved parties. By incorporating Pharmagreen’s propri...

 PRESS RELEASE

PHBI – Pharmagreen Starts Sales of MaxGenomicTM Supplement on Amazon.c...

PHBI – Pharmagreen Starts Sales of MaxGenomicTM Supplement on Amazon.com and Develops Its Next Pre-Workout Formulation CARSON CITY, NV, Sept. 05, 2023 (GLOBE NEWSWIRE) -- via – Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), “Pharmagreen” or the “Company” is pleased to announce that it has been approved by Amazon Seller Central for online sales via Amazon’s e-commerce platform for its MaxGenomicTM Supplement. The company is also developing additional sales channels, both online and brick-and-mortar, for the MaxGenomicTM supplements. Pharmagreen’s long term focus is to develop organic form...

 PRESS RELEASE

PHBI Pharmgreen Launches Online Sales for Its MaxGenomic™ Supplement P...

PHBI Pharmgreen Launches Online Sales for Its MaxGenomic™ Supplement Product CARSON CITY, NV, Feb. 08, 2023 (GLOBE NEWSWIRE) -- via – Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), “Pharmagreen” or the “Company” is pleased to announce that it has completed development of its first formulated nutraceutical product and has commenced online sales via the Shopify ecommerce platform of its MaxGenomic™ Supplement.  The company is also pleased to have entered the nutraceutical industry with this product development and be part of this multi-hundred-billion-dollar industry that is growing at a rec...

 PRESS RELEASE

Pharmagreen Appoints Tyrell Crosby, a Professional Athlete, as Its Hon...

Pharmagreen Appoints Tyrell Crosby, a Professional Athlete, as Its Honorary Sports Ambassador CARSON CITY, NV, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via – Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), (“Pharmagreen” or the “Company”) is pleased to announce that Mr. Tyrell Crosby, a professional NFL player, has joined the Pharmagreen team to be an Honorary Sports Ambassador for Pharmagreen’s NutraMax Genomic Supplement product line. Tyrell will attend gatherings, trade shows, and other scheduled events selected by Pharmagreen, and will provide his endorsement of NutraMax products on various on...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch